Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina(Seagen (United States)), Peter D. Senter(Seagen (United States)), Damon L. Meyer(Seagen (United States)), Michael Torgov(Seagen (United States)), Charles G. Cerveny(Seagen (United States)), Brian A. Mendelsohn(Seagen (United States)), Ron L DeBlanc(Seagen (United States)), Clay B. Siegall(Bristol-Myers Squibb (United States)), Tim D. Bovee(Seagen (United States)), Alan F. Wahl(Seagen (United States)), Dana F. Chace(Seagen (United States)), R Patrick Gearing(Seagen (United States)), Joseph A. Francisco(Seagen (United States)), Brian E. Toki(Seagen (United States))
Cited by 1,183
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Antibody-Drug Conjugates in Cancer Therapy
|Annual Review of Medicine|2012|763